The phase 3 ILLUMINATE-301 study (NCT03445533), evaluated tilsotolimod plus ipilimumab versus ipilimumab alone in patients with PD-1 inhibitor-refractory advanced melanoma, however the study was terminated due to lack of efficacy. The gene discussed is PDCD1; the disease is melanoma.